BOSTON and SHENZHEN, China, June 10, 2026 /PRNewswire/ — XtalPi (2228.HK), a leading platform in artificial intelligence (AI) and robotics-driven drug discovery, today announced a strategic partnership with a prominent international biopharmaceutical company. The collaboration focuses on developing a best-in-class small molecule against a G protein-coupled receptor (GPCR). This agreement builds upon a rigorous and successful pilot phase, where XtalPi's integrated quantum physics and AI algorithms delivered breakthrough hit rates, confirming the platform's capacity to tackle this complex metabolic target. Under the agreement, the partner will provide an upfront payment and fully fund XtalPi's early R&D efforts. In addition, XtalPi…